A detailed history of Dimensional Fund Advisors LP transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 321,447 shares of ATHA stock, worth $186,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares
321,447
Previous 550,353 41.59%
Holding current value
$186,439
Previous $1.46 Million 90.12%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$0.42 - $3.43 $96,140 - $785,147
-228,906 Reduced 41.59%
321,447 $144,000
Q2 2024

Aug 09, 2024

BUY
$1.92 - $2.71 $214,577 - $302,866
111,759 Added 25.48%
550,353 $1.46 Million
Q1 2024

May 10, 2024

BUY
$2.24 - $4.15 $205,609 - $380,928
91,790 Added 26.47%
438,594 $1.2 Million
Q4 2023

Feb 07, 2024

SELL
$1.39 - $2.46 $260,829 - $461,611
-187,647 Reduced 35.11%
346,804 $842,000
Q3 2023

Nov 09, 2023

BUY
$1.9 - $3.16 $221,927 - $369,100
116,804 Added 27.97%
534,451 $1.08 Million
Q2 2023

Aug 09, 2023

BUY
$2.36 - $3.59 $160,829 - $244,651
68,148 Added 19.5%
417,647 $1.23 Million
Q1 2023

May 12, 2023

BUY
$2.26 - $4.22 $729,116 - $1.36 Million
322,618 Added 1200.17%
349,499 $873,000
Q4 2022

Feb 09, 2023

BUY
$2.76 - $3.71 $16,521 - $22,208
5,986 Added 28.65%
26,881 $85,000
Q3 2022

Nov 10, 2022

SELL
$2.93 - $3.96 $16,088 - $21,744
-5,491 Reduced 20.81%
20,895 $62,000
Q2 2022

Aug 12, 2022

SELL
$2.74 - $13.43 $61,307 - $300,496
-22,375 Reduced 45.89%
26,386 $80,000
Q1 2022

May 13, 2022

BUY
$8.96 - $13.51 $436,898 - $658,761
48,761 New
48,761 $658,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $21.9M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.